Braza Discusses eSports, Foley Survey in San Francisco Business Times
August 2, 2018
San Francisco Business Times
Partner Mary K. Braza was quoted in a San Francisco Business Times article, “Esports Joins the Big Leagues,” about how and why professional sports teams like the Golden State Warriors are investing in esports.
“A lot of it depends on the type of owner you have in the traditional sports,” said Braza, who co-chairs Foley’s sports industry team. “The Warriors owners are more interested in new technologies, they’re younger than a lot of owners and they’re more connected to the tech community.”
The article also noted the findings of Foley and The Esports Observer’s new esports survey including concerns about match fixing, net neutrality and illegal gambling.
“A lot of it depends on the type of owner you have in the traditional sports,” said Braza, who co-chairs Foley’s sports industry team. “The Warriors owners are more interested in new technologies, they’re younger than a lot of owners and they’re more connected to the tech community.”
The article also noted the findings of Foley and The Esports Observer’s new esports survey including concerns about match fixing, net neutrality and illegal gambling.
People
Related News
May 1, 2026
In the News
David Rosen Weighs in on SCOTUS Review of Skinny Label Patent Dispute
Foley & Lardner LLP partner David Rosen is featured across the media for his perspective on the U.S. Supreme Court case Hikma Pharmaceuticals v. Amarin Pharma.
April 27, 2026
In the News
Jesse Neil Featured as a Distinguished Leader in Law.com's Southeastern Legal Awards
Foley & Lardner LLP partner Jesse Neil is recognized in Law.com as one of the Distinguished Leader honorees for the 2026 Southeastern Legal Awards.
April 27, 2026
In the News
David Rosen and William Holtz Analyze FDA Approval Speed, Biotech Pressures
Foley & Lardner LLP attorneys David Rosen and William Holtz are quoted in the PharmaVoice article, “FDA’s need for speed could strain small biotechs. Here’s how they can keep up,” examining the FDA’s accelerated drug approval initiatives and its impact on smaller pharmaceutical companies.